NASDAQ:ONCS - OncoSec Medical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.7195 +0.03 (+4.35 %) (As of 01/18/2019 04:00 PM ET)Previous Close$0.7195Today's Range$0.6901 - $0.739952-Week Range$0.54 - $2.21Volume255,728 shsAverage Volume419,889 shsMarket Capitalization$44.51 millionP/E RatioN/ADividend YieldN/ABeta2.05 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response in Phase 1 and 2 clinical trials for metastatic melanoma and triple-negative breast cancer. The company has also completed Phase II studies in metastatic melanoma (OMS-I100) and merkel cell carcinoma (OMS-I110). OncoSec Medical Incorporated has an investigator-sponsored clinical trial with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte (OMS-I102); and a clinical trial collaboration and drug supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of its ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a registration-directed Phase 2b clinical trial referred to as PISCES. This trial would evaluate the combination of therapies in patients with unresectable metastatic melanoma who have progressed. It also has a research collaboration with Avacta Group plc for gene delivery of therapeutic affimers. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California. Receive ONCS News and Ratings via Email Sign-up to receive the latest news and ratings for ONCS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONCS Previous Symbol CUSIPN/A Webwww.oncosec.com Phone855-662-6732Debt Debt-to-Equity RatioN/A Current Ratio5.42 Quick Ratio5.42Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book1.64Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-39,130,000.00 Net MarginsN/A Return on Equity-151.71% Return on Assets-123.34%Miscellaneous Employees34 Outstanding Shares64,510,000Market Cap$44.51 million OptionableNot Optionable OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions What is OncoSec Medical's stock symbol? OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS." How were OncoSec Medical's earnings last quarter? OncoSec Medical Inc (NASDAQ:ONCS) posted its quarterly earnings results on Friday, December, 14th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.06. View OncoSec Medical's Earnings History. When is OncoSec Medical's next earnings date? OncoSec Medical is scheduled to release their next quarterly earnings announcement on Friday, March 8th 2019. View Earnings Estimates for OncoSec Medical. What price target have analysts set for ONCS? 4 equities research analysts have issued twelve-month price objectives for OncoSec Medical's stock. Their predictions range from $3.00 to $5.00. On average, they expect OncoSec Medical's stock price to reach $4.00 in the next year. This suggests a possible upside of 455.9% from the stock's current price. View Analyst Price Targets for OncoSec Medical. What is the consensus analysts' recommendation for OncoSec Medical? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoSec Medical. Has OncoSec Medical been receiving favorable news coverage? Headlines about ONCS stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. OncoSec Medical earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. Who are some of OncoSec Medical's key competitors? Some companies that are related to OncoSec Medical include Zafgen (ZFGN), VBI Vaccines (VBIV), Calithera Biosciences (CALA), Tocagen (TOCA), Recro Pharma (REPH), ProMetic Life Sciences (PFSCF), Molecular Templates (MTEM), Ocular Therapeutix (OCUL), Constellation Pharmaceuticals (CNST), Nature's Sunshine Products (NATR), AcelRx Pharmaceuticals (ACRX), Syndax Pharmaceuticals (SNDX), CytoDyn (CYDY), MOTIF BIO PLC/S (MTFB) and Emisphere Technologies (EMIS). Who are OncoSec Medical's key executives? OncoSec Medical's management team includes the folowing people: Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 54)Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 38)Ms. Sara M. Bonstein, CFO & COO (Age 37)Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer How do I buy shares of OncoSec Medical? Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OncoSec Medical's stock price today? One share of ONCS stock can currently be purchased for approximately $0.7195. How big of a company is OncoSec Medical? OncoSec Medical has a market capitalization of $44.51 million. OncoSec Medical employs 34 workers across the globe. What is OncoSec Medical's official website? The official website for OncoSec Medical is http://www.oncosec.com. How can I contact OncoSec Medical? OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected] MarketBeat Community Rating for OncoSec Medical (NASDAQ ONCS)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 234 (Vote Outperform)Underperform Votes: 175 (Vote Underperform)Total Votes: 409MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe ONCS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: What is the Current Ratio?